The CD14+HLA-DRlo/neg Monocyte: An Immunosuppressive Phenotype That Restrains Responses to Cancer Immunotherapy
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Recent successes in cancer immunotherapy have been tempered by sub-optimal clinical responses in the majority of patients. The impaired anti-tumor immune responses observed in these patients are likely a consequence of immune system dysfunction contributed to by a variety of factors that include, but are not limited to, diminished antigen presentation/detection, leukopenia, a coordinated network of immunosuppressive cell surface proteins, cytokines and cellular mediators. Monocytes that have diminished or no HLA-DR expression, called CD14+HLA-DRlo/neg monocytes, have emerged as important mediators of tumor-induced immunosuppression. These cells have been grouped into a larger class of suppressive cells called myeloid derived suppressor cells (MDSCs) and are commonly referred to as monocytic myeloid derived suppressor cells. CD14+HLA-DRlo/neg monocytes were first characterized in patients with sepsis and were shown to regulate the transition from the inflammatory state to immune suppression, ultimately leading to immune paralysis. These immunosuppressive monocytes have also recently been shown to negatively affect responses to PD-1 and CTLA-4 checkpoint inhibition, CAR-T cell therapy, cancer vaccines, and hematopoietic stem cell transplantation. Ultimately, the goal is to understand the role of these cells in the context of immunosuppression not only to facilitate the development of targeted therapies to circumvent their effects, but also to potentially use them as a biomarker for understanding disparate responses to immunotherapeutic regimens. Practical aspects to be explored for development of CD14+HLA-DRlo/neg monocyte detection in patients are the standardization of flow cytometric gating methods to assess HLA-DR expression, an appropriate quantitation method, test sample type and processing guidances. Once detection methods are established that yield consistently reproducible results, then further progress can be made towards understanding the role of CD14+HLA-DRlo/neg monocytes in the immunosuppressive state.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
Bronte, V., Brandau, S., Chen, S.-H., Colombo, M. P., Frey, A. B., Greten, T. F., Mandruzzato, S., Murray, P. J., Ochoa, A., Ostrand-Rosenberg, S., et al. (2016) · Nature Communications · doi:10.1038/ncomms12150 · Cited by 2,751
CSF-1R inhibition alters macrophage polarization and blocks glioma progression
Pyonteck, S. M., Akkari, L., Schuhmacher, A. J., Bowman, R. L., Sevenich, L., Quail, D. F., Olson, O. C., Quick, M. L., Huse, J. T., Teijeiro, V., et al. (2013) · Nature Medicine · doi:10.1038/nm.3337 · Cited by 2,463 · cited 1×
“, pro-neural glioblastoma) may be more susceptible to the reprogramming of monocytes/macrophages from CSF-1R inhibition (106).”
BackgroundMonocyte deactivation in septic patients: Restoration by IFN-γ treatment
Döcke, W.-D., Randow, F., Syrbe, U., Krausch, D., Asadullah, K., Reinke, P., Volk, H.-D., & Kox, W. (1997) · Nature Medicine · doi:10.1038/nm0697-678 · Cited by 1,190 · cited 1×
“In the early stage of sepsis in these patients, pro-inflammatory cytokines such as TNFα, IL-1, GM-CSF, and IL-6, drove the deactivation of monocytes by down regulating HLA-DR through IL-10 and TGF-β mediated pathways and diminished capacity for pro-inflammatory cytokine production (16, 18).”
BackgroundSystemic Immunity Is Required for Effective Cancer Immunotherapy
Spitzer, M. H., Carmi, Y., Reticker-Flynn, N. E., Kwek, S. S., Madhireddy, D., Martins, M. M., Gherardini, P. F., Prestwood, T. R., Chabon, J., Bendall, S. C., et al. (2017) · Cell · doi:10.1016/j.cell.2016.12.022 · Cited by 963 · cited 1×
“As new evidence suggests that systemic immunity plays an important role in optimal responses to cancer immunotherapy (51, 133), circulating monocytes likely contribute significantly to this phenomenon.”
BackgroundRegulation of MHC Class II Expression by Interferon-γ Mediated by the Transactivator Gene CIITA
Steimle, V., Siegrist, C.-A., Mottet, A., Lisowska-Grospierre, B., & Mach, B. (1994) · Science · doi:10.1126/science.8016643 · Cited by 898 · cited 4×
“IL-1β and TGF-β directly down-regulate transcription of HLA-DR through CIITA and/or prevent IFN-γ induction of HLA-DR (16, 37, 38).”
BackgroundInfluentialCSF-1 receptor signaling in myeloid cells.
Stanley, E. R., & Chitu, V. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a021857 · Cited by 825
Hoechst, B., Ormandy, L. A., Ballmaier, M., Lehner, F., Krüger, C., Manns, M. P., Greten, T. F., & Korangy, F. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.020 · Cited by 793
High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy
Krieg, C., Nowicka, M., Guglietta, S., Schindler, S., Hartmann, F. J., Weber, L. M., Dummer, R., Robinson, M. D., Levesque, M. P., & Becher, B. (2018) · Nature Medicine · doi:10.1038/nm.4466 · Cited by 735 · cited 1×
“In a study of stage IV melanoma patients receiving anti-PD-1 therapy, single cell mass cytometry was used to investigate peripheral blood biomarkers (62).”
MethodChang, A. L., Miska, J., Wainwright, D. A., Dey, M., Rivetta, C. V., Yu, D., Kanojia, D., Pituch, K. C., Qiao, J., Pytel, P., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0144 · Cited by 640
Colony-stimulating factor-1 in immunity and inflammation
Chitu, V., & Stanley, E. R. (2006) · Current Opinion in Immunology · doi:10.1016/j.coi.2005.11.006 · Cited by 635 · cited 1×
“It is hypothesized that blocking the signaling function of this receptor will result in the reduction of monocyte/macrophage infiltration into tumors and consequently limit the immunosuppressive nature of the tumor microenvironment (104).”
BackgroundLe, D. T., Wang-Gillam, A., Picozzi, V., Greten, T. F., Crocenzi, T., Springett, G., Morse, M., Zeh, H., Cohen, D., Fine, R. L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.4244 · Cited by 611
Martens, A., Wistuba-Hamprecht, K., Foppen, M. G., Yuan, J., Postow, M. A., Wong, P., Romano, E., Khammari, A., Dreno, B., Capone, M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2412 · Cited by 541
Valenti, R., Huber, V., Filipazzi, P., Pilla, L., Sovena, G., Villa, A., Corbelli, A., Fais, S., Parmiani, G., & Rivoltini, L. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1819 · Cited by 493
Gebhardt, C., Sevko, A., Jiang, H., Lichtenberger, R., Reith, M., Tarnanidis, K., Holland-Letz, T., Umansky, L., Beckhove, P., Sucker, A., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0676 · Cited by 367
Immunosuppressive CD14+HLA-DRlow/− monocytes in B-cell non-Hodgkin lymphoma
Lin, Y., Gustafson, M. P., Bulur, P. A., Gastineau, D. A., Witzig, T. E., & Dietz, A. B. (2011) · Blood · doi:10.1182/blood-2010-05-283820 · Cited by 244
Self-citationAntonios, J. P., Soto, H., Everson, R. G., Moughon, D., Orpilla, J. R., Shin, N. P., Sedighim, S., Treger, J., Odesa, S., Tucker, A., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/now287 · Cited by 206
Monocyte Human Leukocyte Antigen–DR Transcriptional Downregulation by Cortisol during Septic Shock
Le Tulzo, Y., Pangault, C., Amiot, L., Guilloux, V., Tribut, O., Arvieux, C., Camus, C., Fauchet, R., Thomas, R., & Drénou, B. (2004) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200309-1329oc · Cited by 166 · cited 1×
“Down-regulation of HLA-DR on monocytes has been observed in response to cortisol (41), prednisolone (42), and dexamethasone (43, 44).”
BackgroundStroncek, D. F., Ren, J., Lee, D. W., Tran, M., Frodigh, S. E., Sabatino, M., Khuu, H., Merchant, M. S., & Mackall, C. L. (2016) · Cytotherapy · doi:10.1016/j.jcyt.2016.04.003 · Cited by 148
de Coaña, Y. P., Wolodarski, M., Poschke, I., Yoshimoto, Y., Yang, Y., Nyström, M., Edbäck, U., Brage, S. E., Lundqvist, A., Masucci, G. V., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15368 · Cited by 139
Cited by
Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment
Schulte-Schrepping, J., Reusch, N., Paclik, D., Baßler, K., Schlickeiser, S., Zhang, B., Krämer, B., Krammer, T., Brumhard, S., Bonaguro, L., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.001 · Cited by 1,461
“CD14+HLA-DRlo monocytes have also been implicated with immunosuppression in cancer patients (Bronte et al., 2016;Mengos et al., 2019; Meyer et al., 2014).”
Metadata
- Authors
- Mengos, A. E., Gastineau, D. A., & Gustafson, M. P.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2019-05-22
- Volume
- 10
- Pages
- 1147-1147
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2944833967
- Cited by
- 160
- References
- 19
- FWCI
- 6.09
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.